Evaluation of the Effect of the Ni-Thiosemicarbazones complex on Expression Changes of CPEB2 gene in Acute lymphoblastic leukemia
Evaluation of the Effect of the Ni-Thiosemicarbazones complex on Expression Changes of CPEB2 gene in Acute lymphoblastic leukemia
Arezoo Hassani,1Mahnaz Eskandari,2Golnaz Asaadi Tehrani,3,*Sina Mirza Ahmadi,4
1. Msc of Molecular Genetic Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran. 2. Msc of Molecular Genetic Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran. 3. Assistant professor of Molecular Genetics, Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran. 4. Assistant professor of Molecular Genetics Department of Genetics, Zanjan Branch, Islamic Azad University, Zanjan, Iran.
Introduction: The aberrant proliferation and differentiation of a clonal
population of lymphoid cells are involved in the pathogenesis of ALL. ALL has a poor
prognosis, with only 10% of adult ALL patients surviving and 30% of pediatric ALL patients
surviving. The complete remission rate in adult ALL is 30 percent to 40 percent in the first
relapse and 20 to 25 percent in the second relapse with conventional chemotherapy. CPEB2 is
increased in cancer tissues and increases the proliferation and migration of cancer cells of this
kind. Thiosemicarbazones (TSCs) are a type of Schiff base made by combining
thiosemicarbazone with an appropriate aldehyde or ketone. Chemists and biologists have been
studying TSCs because of their diverse pharmacological properties. The application of these
outstanding metal chelators against cancer is one of the promising areas in which they are being
developed. The goal of this study was to see how Ni-thiosemicarbazone complexes affected
the expression of the CPEB2 gene in a cell line that had been diagnosed with acute
lymphoblastic leukemia.
Methods: In the current research, two concentrations of Ni-Thiosemicarbazone
complexes were prepared: 51µM and 61µM at 48h. The Jurkat E6.1 cell line was purchased
from Pasteur Institute and treated with prepared doses of the Thiosemicarbazones complexes
Ni at 24 and 48 hours after cell passage. The expression changes of CPEB2 and GAPDH were
studied using Real-Time PCR after RNA extraction and cDNA synthesis. Finally, Rest 2002
Software was used to analyze the data, and Excel was used to draw the diagrams.
Results: The results of our findings showed that the expression of CPEB2 in comparison with
the GAPDH housekeeping gene increase after 48 hours of Ni-Thiosemicarbazone complexes.
According to the findings, changes in CPEB2 gene expression increased after 48 hours at a
concentration of 51µM and 61µM were changes expression included 51µM (1.243) and 61µM
(1.502) at 48 hours, respectively. (P <0.001)
Conclusion: According to the present study results, alternation in CPEB2
expression after treatment with Ni-Thiosemicarbazone complexes, at tow concentration were
ineffective in decrease of CPEB2 expression. Evidence showed that the Ni-Thiosemicarbazone
complexes does not have positive potential and efficacy because the drug was ineffective in
decreasing gene expression in tow concentrations in 48 hours (p-value 0.001). And it is
suggested to study the mentioned gene in order to further investigate the therapeutic potential
of Ni-Thiosemicarbazone complexes in other concentrations and times.